Patients with triple-negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer participated in a first-in-human clinical trial.
Scancell, a cancer and infectious disease treatment company, has announced that the first patient in its multicentre Modi-1 clinical trial (ModiFY) has been enrolled and treated at Imperial College London's Hammersmith Hospital.
The research is a first-in-human clinical trial for triple-negative breast, ovarian, head and neck, and renal cancer patients.
Scancell's Modi-1 is the company's first candidate in the Moditope platform, and the open-label study will enrol up to 108 patients across 20 clinical trial sites in the United Kingdom. The first part of the trial's goal is to evaluate the safety and immunogenicity of two citrullinated vimentin peptides, and if no substantial side effects are found, a citrullinated enolase peptide will be added.
Furthermore, the effect of Modi-1 on promoting T-cell infiltration into the tumour will be evaluated in a cohort of 30 patients with head and neck cancer who will be given Modi-1 before their first surgical resection.
Professor Lindy Durrant, CEO of Scancell, said: "This is the first time a product from our Moditope platform has been tested in cancer patients, and it marks a significant milestone for the company. We are hopeful about Modi-1's broad clinical utility, and we plan to rapidly recruit patients across all four cancers after completing safety assessments in the first few cohorts."
Medical oncologist and principal investigator, Dr. David Pinato, of Imperial College London's Hammersmith Hospital, added: "The scientific rationale for using Moditope to treat patients is compelling, and it was simple to administer to our first patient in clinical practise. Many important clinical questions in patients with unmet needs will be addressed in this study."
Meanwhile, the Modi-1 peptides have been linked to Amplivant, a powerful adjuvant that boosts the immune response and leads to highly efficient tumour clearance in preclinical models, including protection against recurrence. ISA Pharmaceuticals has a worldwide licensing and collaboration agreement with Modi-1 for the manufacturing, development, and commercialization of the therapy.
Early safety and immunogenicity data will be available later in 2022, and efficacy data in 2023, according to Scancell.
World BI Group examines how research like this could affect drug clinical trials and innovation and all the challenges that come along with it. This year's 19th Clinical Trials Innovation Programmes and 20th Clinical Trials Innovation Programmes will highlight the future of clinical trials and drug development post-COVID and will feature tailored sessions presented by the leading experts from across the globe, so if you’re someone interested in the pharmaceutical industry, we encourage you to attend the 19th Clinical Trials Innovation Programmes and 20th Clinical Trials Innovation Programmes, which are prominent platforms for interacting with the world's most influential and dynamic professionals. With the 19th Clinical Trials Innovation Programmes and 20th Clinical Trials Innovation Programmes, learn how modernization in R&D processes is fundamentally changing what clinical trial research will look like in the next two to five years. So, join us in October 2022 for an in-person experience and two days of top-level strategic content and current scientific insights, networking, and discussions with top global pharmaceutical R&D executives. We are bringing together the best in the industry to help you learn, grow, and accelerate your drug development journey. This event will give you a chance to attend and get a complete learning experience about the challenges and their solutions from experts in the field. Register now to meet new clients, build your brand, get a handle on the market and drive new business.